Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts
- Author(s)
- Taieb, J; Basile, D; Seligmann, J; Argiles, G; André, T; Gallois, C; Goldberg, RM; Yothers, G; Sobrero, A; Meyerhardt, JA; Souglakos, J; Labianca, R; Iveson, T; Church, DN; Arnold, D; Tie, J; Gill, S; Laurent-Puig, P; Yoshino, T; Lonardi, S; Shi, Q;
- Journal Title
- European Journal of Cancer
- Abstract
- BACKGROUND: Despite contributions provided by the recent clinical trials, several issues and challenges still remain unsolved in adjuvant colon cancer (CC). Hence, further studies should be planned to better refine risk assessment as well as to establish the optimal treatment strategy in the adjuvant setting. However, it is necessary to request adequate, contemporary and relevant variables and report them homogeneously in order to bring maximal information when analyzing their prognostic value. MATERIAL AND METHODS: The project was devised to gain a consensus from experts engaged in the planning, accrual and analyses of stage II and III CC clinical trials, to identify mandatory and recommended baseline variables in order to i) harmonize future data collection worldwide in clinical trials dedicated to adjuvant treatment of CC; ii) propose guidance for Case Report Forms to be used for clinical trials in this setting. A total of 72 questions related to variables that should be reported and how to report them in adjuvant clinical trials were approved and then voted to reach a final consensus from panelists. RESULTS: Data items on patient-related factors, histopathological features, molecular profile, circulating biomarkers and blood analyses were analyzed and discussed by the whole expert panel. For each item, we report data supporting the acquired consensus and the relevant issues that were discussed. Nineteen items were deemed to be mandatory for resected stage III patients and 24 for resected stage II disease. In addition, 9 and 4 items were judged as recommended for stage III and II, respectively. CONCLUSION: In our opinion, these 28 variables should be used and uniformly reported in more comprehensive CRFs as research groups design future clinical trials in the field of adjuvant colon cancer.
- Publisher
- Elsevier
- Keywords
- Humans; *Colonic Neoplasms/therapy/pathology; *Consensus; Chemotherapy, Adjuvant/standards; Data Collection/standards; Clinical Trials as Topic/standards; Adjuvant trials; Clinical research guidance; Early colon cancer; Prognostication
- Research Division(s)
- Personalised Oncology
- PubMed ID
- 38810317
- Publisher's Version
- https://doi.org/10.1016/j.ejca.2024.114118
- Open Access at Publisher's Site
https://doi.org/10.1016/j.ejca.2024.114118- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-06-24 11:30:01
Last Modified: 2024-06-24 12:17:25